

# Kienan I Savage

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740763/publications.pdf>

Version: 2024-02-01

35  
papers

2,202  
citations

430442

18  
h-index

414034

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

4423  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw199.	3.0	338
2	Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 14806-14811.	1.6	254
3	Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. <i>Nature</i> , 2008, 453, 677-681.	13.7	220
4	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. <i>Molecular Cell</i> , 2014, 54, 445-459.	4.5	146
5	Use of the $\text{H}^3$ -H2AX Assay to Investigate DNA Repair Dynamics Following Multiple Radiation Exposures. <i>PLoS ONE</i> , 2013, 8, e79541.	1.1	143
6	BRCA1, a hHR23A complex protein involved in the maintenance of genomic stability. <i>FEBS Journal</i> , 2015, 282, 630-646.	2.2	141
7	BRCA1-BARD1 Complexes Are Required for p53 Ser-15 Phosphorylation and a G1/S Arrest following Ionizing Radiation-induced DNA Damage. <i>Journal of Biological Chemistry</i> , 2004, 279, 31251-31258.	1.6	137
8	BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription. <i>Cancer Research</i> , 2010, 70, 2538-2547.	0.4	115
9	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. <i>Cancer Research</i> , 2014, 74, 2773-2784.	0.4	94
10	The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin. <i>Cell Reports</i> , 2015, 11, 149-163.	2.9	82
11	The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. <i>Nucleic Acids Research</i> , 2017, 45, 12816-12833.	6.5	79
12	hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. <i>Nucleic Acids Research</i> , 2011, 39, 1692-1702.	6.5	70
13	Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. <i>Cancer Research</i> , 2015, 75, 2159-2165.	0.4	58
14	Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. <i>Nucleic Acids Research</i> , 2011, 39, 9536-9548.	6.5	43
15	KrÄppel-associated Box (KRAB)-associated Co-repressor (KAP-1) Ser-473 Phosphorylation Regulates Heterochromatin Protein 1 $\beta$ (HP1- $\beta$ ) Mobilization and DNA Repair in Heterochromatin. <i>Journal of Biological Chemistry</i> , 2012, 287, 28122-28131.	1.6	43
16	NF- $\kappa$ B is a critical mediator of BRCA1-induced chemoresistance. <i>Oncogene</i> , 2014, 33, 713-723.	2.6	41
17	PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. <i>Journal of Pathology</i> , 2011, 224, 564-574.	2.1	32
18	Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011, 16, 311-320.	2.2	29

#	ARTICLE	IF	CITATIONS
19	Dual roles of DNA repair enzymes in RNA biology/post-transcriptional control. Wiley Interdisciplinary Reviews RNA, 2016, 7, 604-619.	3.2	19
20	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer Research, 2022, 82, 819-830.	0.4	16
21	Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML. Journal of Translational Medicine, 2020, 18, 339.	1.8	15
22	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. British Journal of Cancer, 2022, 126, 247-258.	2.9	14
23	Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Scientific Reports, 2019, 9, 2678.	1.6	12
24	Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers. Journal of Pathology: Clinical Research, 2020, 6, 146-153.	1.3	12
25	Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. Npj Breast Cancer, 2021, 7, 38.	2.3	12
26	COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks. Communications Biology, 2021, 4, 484.	2.0	8
27	A TMA De-Arraying Method for High Throughput Biomarker Discovery in Tissue Research. PLoS ONE, 2011, 6, e26007.	1.1	8
28	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA. Cancer Research, 2019, 79, 2072-2075.	0.4	6
29	Protein kinase C zeta suppresses low- or high-grade colorectal cancer (CRC) phenotypes by interphase centrosome anchoring. Journal of Pathology, 2018, 244, 445-459.	2.1	4
30	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. BMJ Open, 2018, 8, e023115.	0.8	3
31	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3
32	STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia. Blood, 2019, 134, 1255-1255.	0.6	3
33	BRCA1 and BRCA2: Role in the DNA Damage Response, Cancer Formation and Treatment. , 2009, , 415-443.		2
34	Loss of Function Cohesin Complex Gene Mutations Create Neomorphic Cell States Advantageous to Oncogenesis. Blood, 2016, 128, 1564-1564.	0.6	0
35	The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients. Blood, 2018, 132, 2812-2812.	0.6	0